Correspondence 0001493152-25-005917 from CDT Equity Inc. (CDT)

CDT Equity Inc.
Date: Feb. 11, 2025 · CIK: 0001896212 · Accession: 0001493152-25-005917

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-284714

Date

Feb. 11, 2025

Author

CONDUIT

Form

CORRESP

Company

CDT Equity Inc.

Letter

Conduit Pharmaceuticals Inc.

Tamiami Trail North, Suite 200

Naples, Florida 34103

(648) 491-9132

February 11, 2025

VIA EDGAR SUBMISSION

U.S. Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Conduit Pharmaceuticals Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-284714) (the “Registration Statement”)

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, the Company hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement to become effective on February 12, 2025, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable, unless the Company notifies you otherwise prior to such time.

If you have any questions regarding this request, please contact our outside counsel, Todd Mason of Thompson Hine LLP, by telephone at (212) 908-3946 or via email at Todd.Mason@ThompsonHine.com. Please also call Todd Mason as soon as the Company’s Registration Statement has been declared effective. Thank you for your attention to this matter.

Sincerely,
CONDUIT
PHARMACEUTICALS Inc.

Show Raw Text

CORRESP
1
filename1.htm

Conduit
Pharmaceuticals Inc.

4581
Tamiami Trail North, Suite 200

Naples,
Florida 34103

(648)
491-9132

February
11, 2025

VIA
EDGAR SUBMISSION

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Conduit
    Pharmaceuticals Inc. (the “Company”)

    Registration
    Statement on Form S-3 (File No. 333-284714) (the “Registration Statement”)

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the Securities Act of 1933, as amended, the Company hereby requests that the U.S. Securities and Exchange Commission
take appropriate action to cause the above-referenced Registration Statement to become effective on February 12, 2025, at 4:30 p.m.,
Eastern Time, or as soon thereafter as is practicable, unless the Company notifies you otherwise prior to such time.

If
you have any questions regarding this request, please contact our outside counsel, Todd Mason of Thompson Hine LLP, by telephone at (212)
908-3946 or via email at Todd.Mason@ThompsonHine.com. Please also call Todd Mason as soon as the Company’s Registration Statement
has been declared effective. Thank you for your attention to this matter.

    Sincerely,

    CONDUIT
    PHARMACEUTICALS Inc.

    By:
    /s/
    David Tapolczay

    Name:
    David
    Tapolczay

    Title:
    Chief
    Executive Officer

    cc:
    Todd
    Mason, Thompson Hine LLP

SecProbe.io